Abstracts tagged "Immunotherapy"

Abstract Number: 84 • 2019 ACR/ARP Annual Meeting
Cenerimod, a Potent and Selective Sphingosine-1-Phosphate Receptor 1 Modulator, Controls Systemic Autoimmunity and Organ Pathology in Mouse Models of Systemic Lupus Erythematosus and Sjögren’s Syndrome
Estelle Gerossier ¹, Saba Nayar ², Charlotte Smith ², Sylvie Froidevaux ³, Francesca Barone ² and Marianne Martinic¹, ¹Idorsia Pharmaceuticals Ltd., Allschwil, Basel-Landschaft, Switzerland, ²Rheumatology Research Group, University of Birmingham, Birmingham, United Kingdom, ³Idorsia Pharmaceuticals Ltd., Allschwil, Switzerland
Background/Purpose: Autoimmune diseases including SLE and SS are characterized by aberrant lymphocyte activation and autoantibody production. This results in systemic manifestations and the formation of…
Abstract Number: 253 • 2019 ACR/ARP Annual Meeting
A Systematic Review and Meta-analysis of Observational Studies Reporting on the Use of Checkpoint Inhibitors in Patients with Cancer and Pre-existing Autoimmune Disease
Maria Lopez-Olivo¹, Noha Abdel-Wahab ¹ and Maria E. Suárez-Almazor ², ¹The University of Texas, MD Anderson Cancer Center, Houston, TX, ²Department of Rheumatology/Clinical Immunology, The University of Texas MD Anderson Cancer Center, Houston, TX , USA., Houston, TX
Background/Purpose: Immune checkpoint inhibitors (ICI) are increasingly used in the treatment of cancer. To date, no clinical trials exist evaluating the use of ICI in…
Abstract Number: 1339 • 2019 ACR/ARP Annual Meeting
Risk of Immunotherapy Related Toxicity in Patients with Rheumatoid Arthritis
Elizaveta Efuni ¹, Samuel Cytryn ², Patrick Boland ² and Sabina Sandigursky³, ¹New York University School of Medicine, New York, NY, ²NYU Langone Health, New York, ³NYU Langone Health, New York, NY
Background/Purpose: Immune checkpoint inhibitors (ICIs) have changed the therapeutic landscape in oncology leading to cures in some cancer types. However, patients with pre-existing autoimmune diseases…
Abstract Number: 1808 • 2019 ACR/ARP Annual Meeting
Immune Checkpoint Inhibitor-Induced Inflammatory Arthritis Persists After Immunotherapy Cessation
Tawnie Braaten¹, Julie Brahmer ¹, Patrick Forde ¹, Dung Le ¹, Evan Lipson ¹, Jarushka Naidoo ¹, Megan Schollenberger ¹, Lei Zheng ¹, Michelle Jones ¹, Ami Shah ², Clifton Bingham ³ and Laura Cappelli ³, ¹Johns Hopkins, Baltimore, MD, ²Johns Hopkins Hospital, Baltimore, MD, ³Johns Hopkins University, Baltimore, MD
Background/Purpose: The use of immune checkpoint inhibitor (ICI) therapy for malignancy is growing. Various autoimmune and inflammatory syndromes, known as immune-related adverse events (irAEs) have…
Abstract Number: 1956 • 2019 ACR/ARP Annual Meeting
Characterizing Arthritis Related to Immune Checkpoint Inhibitors Using Synovial Fluid and Matched Blood
Mazen Nasrallah¹, Molly Thomas ², Kasidet Manakongtreecheep ², Daniel Zlotoff ², Aleigha Lawless ², Hellen Giang ², Sara Schoenfeld ², Ryan Sullivan ², Genevieve Boland ², Kerry Reynolds ², Minna Kohler ², Andrew Luster ² and Alexandra-Chloé Villani ², ¹Massachusetts General Hospital, Boston, ²MGH, Boston
Background/Purpose: Monoclonal antibodies against CTLA-4 and PD-1 have revolutionized the field of immuno-oncology over the past decade. These therapies however are limited by immune related…
Abstract Number: 2137 • 2019 ACR/ARP Annual Meeting
Overall Survival in Patients with PD-1 Inhibitor-related Inflammatory Arthritis and Metastatic Melanoma
Michael Richter¹, Jacob Orme ², Heidi Finnes ³ and Uma Thanarajasingam ⁴, ¹Division of Rheumatology, University of Washington, Seattle, WA, ²Department of Hematology and Oncology, Mayo Clinic, Rochester, MN, ³Department of Pharmacy, Mayo Clinic, Rochester, ⁴Mayo Clinic, Rochester, MN
Background/Purpose: The development of de novo inflammatory arthritis (IA) occurs in 2-4% of all patients with cancer treated with programmed cell death protein 1 (PD-1)…
Abstract Number: 2139 • 2019 ACR/ARP Annual Meeting
Rheumatic Immune-Related Adverse Events Associated with Treatment with Immune Checkpoint Inhibitors: A Multicenter Study of 38 Cases
Sebastian Rodriguez-Garcia¹, David Lobo ², Fabiola Ojeda ³, Raul Castellanos-Moreira ⁴, Ana Laiz ², Roberto Gumucio ⁴, Cesar Diaz-Torné ², Virginia Ruiz-Esquide ⁵, Milena Millan ², Ivan Castellvi ⁶, Patricia Moya Alvarado ⁷, Berta Magallares ², Carolina Perez ³, Hector Corominas ⁸ and Jose Gomez-Puerta ⁹, ¹Rheumatology Department. Hospital Clínic Barcelona, Barcelona, Spain, ²Rheumatology Department. Hospital Sant Pau, Barcelona, Catalonia, Spain, ³Rheumatology Department. Hospital del Mar, Barcelona, Catalonia, Spain, ⁴Rheumatology Department. Hospital Clínic Barcelona, Barcelona, Catalonia, Spain, ⁵Department of Rheumatology, Hospital Clínic, Barcelona, Barcelona, Catalonia, Spain, ⁶Hospital de la Santa Creu i Sant Pau, Barcelona, Spain, ⁷Hospital de la Santa Creu i Sant Pau, Barcelona, Catalonia, Spain, ⁸Rheumatology Department, Hospital Sant Pau, Barcelona, Catalonia, Spain, ⁹Department of Rheumatology, Hospital Clínic, Barcelona, Barcelona, Spain
Background/Purpose: Immune checkpoint inhibitors (ICI) against CTLA-4 or PD- 1/PD-L1 and more recently TIM3, have demonstrated efficacy in improving the survival of patients with diverse…
Abstract Number: 2140 • 2019 ACR/ARP Annual Meeting
Preexisting Autoimmune Disease and Rheumatic Immune-Related Adverse Events Associated with Cancer Immunotherapy: A Case Series from the Canadian Research Group of Rheumatology in Immuno-Oncology (CanRIO)
Linda Laaouad¹, Janet Roberts ², Daniel Ennis ³, Carrie Ye ⁴, Karam Al Jumaily ⁵, Marie Hudson ⁶, Shahin Jamal ⁷, Janet Pope ⁸, Tatiana Nevskaya ⁹, Alexandra Saltman ¹⁰, Megan Himmel ¹¹, Aurore Fifi-Mah ¹², Annaliese Tisseverasinghe ¹³, Nancy Maltez ¹⁴, Ines Colmegna ¹⁵ and Sabrina Hoa ¹⁶, ¹University of Montreal, Montreal, Canada, ²Dalhousie University, Halifax, Canada, ³University of Toronto, Toronto, ON, Canada, ⁴University of Alberta, Edmonton, AB, Canada, ⁵University of Alberta, Edmonton, Canada, ⁶Jewish General Hospital, Lady Davis Institute for Medical Research, and Department of Medicine, McGill University, Montreal, QC, Canada, ⁷University of British Columbia, Vancouver, BC, Canada, ⁸Western University, London, ON, Canada, ⁹University of Western Ontario, London, ON, Canada, ¹⁰University of Toronto, Mount Sinai Hospital and Princess Margaret Cancer Centre, Toronto, ON, Canada, ¹¹University of Toronto, Toronto, Canada, ¹²University of Calgary, Calgary, AB, Canada, ¹³University of Manitoba, Winnipeg, MB, Canada, ¹⁴University of Ottawa, Ottawa, ON, Canada, ¹⁵McGill University Health Center, Montreal, QC, Canada, ¹⁶University of Montreal, Montreal, QC, Canada
Background/Purpose: Immune checkpoint inhibitors (ICIs) have revolutionized cancer therapy by harnessing the immune system to fight cancer, but are associated with significant immune-related adverse events…
Abstract Number: 2146 • 2019 ACR/ARP Annual Meeting
Complications of Immune Checkpoint Inhibitor Therapy in Patients with and Without Pre-existing Rheumatologic Disease
Emily Carroll¹, Amanda Leiter ², Danielle Brooks ¹, Jennifer Ben Shimol ³, Elliot Eisenberg ¹, Matthew Galsky ⁴, Emily Gallagher ⁵ and Margrit Wiesendanger ³, ¹Department of Medicine, Icahn School of Medicine at Mount Sinai, New York, ²Division of Endocrinology, Department of Medicine, Icahn School of Medicine at Mount Sinai, New York, ³Division of Rheumatology, Department of Medicine, Icahn School of Medicine at Mount Sinai, New York, ⁴Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, ⁵Division of Endocrinology, Department of Medicine, Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York
Background/Purpose: Immune checkpoint inhibitors (ICIs) are effective therapies in the treatment of many cancers, but their use has been linked with immune-related adverse events (irAEs).…
Abstract Number: 2147 • 2019 ACR/ARP Annual Meeting
Musculoskeletal Ultrasound Enhances the Evaluation of Checkpoint Inhibitor Associated Musculoskeletal Immune Related Adverse Events
Mazen Nasrallah¹, Sara Schoenfeld ², Mark Matza ¹, Donald Lawrence ², Justine Cohen ², Meghan Mooradian ², Kerry Reynolds ², Ryan Sullivan ² and Minna Kohler ², ¹Massachusetts General Hospital, Boston, ²MGH, Boston
Background/Purpose: Cancer immunotherapy with monoclonal antibodies that antagonize molecular checkpoint pathways in immune activation, the PD-1/PDL1 axis and CTLA-4, have revolutionized the treatment of solid…
Abstract Number: 2157 • 2019 ACR/ARP Annual Meeting
Checkpoint Inhibitor-Associated Arthritis: Phenotype, Steroid Dose, Serology and Survival
Karmela Kim Chan ¹, Aidan Tirpack ¹, Caroline Benson ¹, Gregory Vitone ¹, Jackie Finik ², Vivian Bykerk ³, Susan Goodman ⁴, Laura Donlin ⁵, Deepak Rao ⁶ and Anne Bass⁴, ¹Hospital For Special Surgery, New York, ²Hospital for Special Surgery, New York, NY, New York, NY, ³Hospital for Special Surgery, New York City, NY, ⁴Hospital For Special Surgery/Weill Cornell Medicine, New York, NY, ⁵Hospital For Special Surgery, New York, NY, ⁶Brigham and Women's Hospital, Boston, MA
Background/Purpose: Previous studies suggest that steroid dose1and rheumatoid factor positivity2 impact cancer survival in checkpoint inhibitor (CI)-treated patients (with CI-associated hypophysitis, and in all-comers with non-small…
Abstract Number: 2158 • 2019 ACR/ARP Annual Meeting
Rheumatic Immune Related Adverse Events Associated with Cancer Immunotherapy: A Nationwide Multi-centre Canadian Cohort from the Canadian Research Group of Rheumatology in Immuno-oncology (CanRIO)
Janet Roberts¹, Daniel Ennis ², Marie Hudson ³, Carrie Ye ⁴, Alexandra Saltman ⁵, Sabrina Hoa ⁶, Janet Pope ⁷, Megan Himmel ², Nancy Maltez ⁸, Aurore Fifi-Mah ⁹, Annaliese Tisseverasinghe ¹⁰, Robert Rottapel ¹¹, Karam Al Jumaily ¹², Christina Ly ¹³, Liliana Cartagena ¹⁴ and Shahin Jamal ¹⁵, ¹Dalhousie University, Halifax, NS, Canada, ²University of Toronto, Toronto, ON, Canada, ³Jewish General Hospital, Lady Davis Institute for Medical Research, and Department of Medicine, McGill University, Montreal, QC, Canada, ⁴University of Alberta, Edmonton, AB, Canada, ⁵University of Toronto, Mount Sinai Hospital and Princess Margaret Cancer Centre, Toronto, ON, Canada, ⁶University of Montreal, Montreal, QC, Canada, ⁷Western University, London, ON, Canada, ⁸University of Ottawa, Ottawa, ON, Canada, ⁹University of Calgary, Calgary, AB, Canada, ¹⁰University of Manitoba, Winnipeg, MB, Canada, ¹¹University of Toronto, Toronto, Canada, ¹²University of Alberta, edmonton, Canada, ¹³McGill University, Montreal, Canada, ¹⁴Arthritis Research Canada, Vancouver, Canada, ¹⁵University of British Columbia, Vancouver, BC, Canada
Background/Purpose: Immune checkpoint inhibitors (ICI) have revolutionized cancer therapy by harnessing the immune system to fight cancer. They are associated with the development of autoimmune…
Abstract Number: 2683 • 2018 ACR/ARHP Annual Meeting
Selective Expansion and Targeting of FoxP3+CD127lo Regulatory T Cells By Low-Dose IL-2 Therapy in Active SLE
Jens Humrich¹, Caroline von Spee-Mayer², Philipp Enghard³, Angelika Rose⁴, Elise Siegert⁵, Tobias Alexander⁵, Falk Hiepe⁶, Gerd R. Burmester⁷ and Gabriela Riemekasten⁸, ¹Department of Rheumatology, University Hospital Schleswig-Holstein - Campus Lübeck, Lübeck, Germany, ²Immunology, University Hospital Freiburg, Freiburg, Germany, ³Department of Nephrology, Charité – University Medicine Berlin, Berlin, Germany, ⁴Rheumatology and Clinical Immunology, Charité – University Medicine Berlin, Berlin, Germany, ⁵Rheumatology and Clinical Immunology, Charité - University Medicine Berlin, Berlin, Germany, ⁶Rheumatology, Charité – University Medicine Berlin, Berlin, Germany, ⁷Rheumatology and Clinical Immunology, Charité-University Medicine Berlin, Berlin, Germany, ⁸Rheumatology, University Hospital Schleswig-Holstein - Campus Lübeck, Lübeck, Germany
Background/Purpose: Interleukin-2 (IL-2) is crucial for the growth and survival of regulatory T cells (Treg), and thus for the control of autoimmunity. In previous studies…
Abstract Number: 346 • 2018 ACR/ARHP Annual Meeting
Immune-Related Adverse Events: Development of a Pilot Immune-Related Adverse Events Clinic for Expedited and Effective Patient Care
Pankti Reid¹ and Reem Jan², ¹Internal Medicine, rheumatology, University of Chicago, Chicago, IL, ²Medicine, Rheumatology, University of Chicago, Chicago, IL
Background/Purpose: The growing use of cancer immunotherapy and checkpoint inhibitors has led to a steep rise in immune-related adverse events (irAEs). Despite expanding research efforts,…
Abstract Number: 2976 • 2018 ACR/ARHP Annual Meeting
Immune Checkpoint Inhibitor-Associated Myositis: A Characteristic Phenotype with a Poor Outcome Related to Concomitant Myocarditis
Celine Anquetil^1,2, Joe-Elie Salem^3,4, Benedicte Lebrun-Vignes⁵, Douglas B Johnson⁶, Andrew Mammen^7,8, Werner Stenzel⁹, Sarah Leonard-louis¹⁰, Olivier Benveniste^11,12, Javid J Moslehi³ and Yves Allenbach^2,13, ¹Internal Medicine and Clinical Immunlogy, Assistance Public - Hopitaux de Paris, Pitié-Salpêtrière University Hospital, PARIS, France, ²CDR en myologie UMR974,, Institut National de la Santé et de la Recherche Médicale, Association Institut de Myologie, PARIS, France, ³Division of Cardiovascular Medicine and Cardio-Oncology Program, Department of Medicine, Vanderbilt University Medical Center, Nasheville, TN, ⁴Department of Pharmacology, Regional Center of Pharmacovigilance, INSERM, CIC-1421, Paris, France, ⁵Department of Pharmacology, Regional Center of Pharmacovigilance, INSERM, CIC-1421, PARIS, France, ⁶Division of Oncology, Department of Medicine, Vanderbilt University Medical Center, Nasheville, TN, ⁷National Institute of Arthritis and Musculoskeletal and Skin Diseases, National Institutes of Health, Bethesda, MD, ⁸Neurology, Johns Hopkins University School of Medicine, Baltimore, MD, ⁹Charité - Universitätsmedizin, Department of Neuropathology, Berlin, Germany, Berlin, Germany, ¹⁰Département de Neuropathologie, Centre de Référence des Maladies Neuro-Musculaires Paris Est, Assistance Publique – Hôpitaux de Paris (AP-HP), Hôpital Universitaire Pitié-Salpêtrière, Paris, France, ¹¹Department of Internal Medicine and Clinical Immunology and Inflammation-Immunopathology-Biotherapy Department (I2B), Pitié-Salpêtrière University Hospital, Assistance Publique-Hôpitaux de Paris, East Paris Neuromuscular Diseases Reference Center, Paris, France, ¹²Centre de Recherche en Myologie, UMRS974, Institut National de la Santé et de la Recherche Médicale, Association Institut de Myologie, Paris, France, ¹³Internal Medicine and Clinical Immunology, Sorbonne University - Assistance Public - Hopitaux de Paris, Pitié-Salpêtrière University Hospital, Paris, France
Background/Purpose: Immune checkpoint inhibitors (ICI) are a major breakthrough in cancer treatment providing frequent durable responses and improving overall survival. Blocking immune checkpoints (Programmed cell…